Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,666 | -21,427 | -95,568 | -55,275 | -119,337 |
| Depreciation Amortization | 535 | 735 | 839 | 782 | 396 |
| Accounts receivable | 2,246 | -9,923 | -4,819 | -7,712 | N/A |
| Accounts payable and accrued liabilities | -1,385 | -6,856 | -919 | 4,180 | 852 |
| Other Working Capital | -3,649 | -19,734 | -10,371 | -7,284 | 3,444 |
| Other Operating Activity | 16,205 | 29,973 | 34,917 | -37,247 | 23,414 |
| Operating Cash Flow | $-15,714 | $-27,232 | $-75,921 | $-102,556 | $-91,231 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -667 | -175 |
| Purchase Sale Intangibles | N/A | N/A | N/A | -300 | N/A |
| Other Investing Activity | 0 | 0 | 0 | 61,710 | -2,610 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $61,043 | $-2,785 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 4,311 | 100 | 84 | 108,314 | 2,004 |
| Financing Cash Flow | $4,311 | $100 | $84 | $108,314 | $2,004 |
| Exchange Rate Effect | 0 | 7 | 35 | 129 | -490 |
| Beginning Cash Position | 78,637 | 105,762 | 181,564 | 114,634 | 207,136 |
| End Cash Position | 67,234 | 78,637 | 105,762 | 181,564 | 114,634 |
| Net Cash Flow | $-11,403 | $-27,125 | $-75,802 | $66,930 | $-92,502 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,714 | -27,232 | -75,921 | -102,556 | -91,231 |
| Capital Expenditure | N/A | N/A | N/A | -667 | -175 |
| Free Cash Flow | -15,714 | -27,232 | -75,921 | -103,223 | -91,406 |